All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Mutation testing in AML:
What you need to know
with Charles Craddock, Ralph Hills, and Gail Roboz
Wednesday, April 23, 2025
17:30-18:30 BST
This independent educational activity is supported by Thermo Fisher Scientific. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through a grant from Bristol Myers Squibb and Servier. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR congress coverage
Bookmark this article
Stay up to date with the latest developments in acute myeloid leukemia with our live social media coverage from the the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, February 12–16, Honolulu, US.
CONGRESS | #Tandem25 | PRESENTATION@NelliBejanyanMD, @MoffittNews, presents findings from a phase I trial evaluating ex-vivo expanded donor gamma delta T cell (GDT) immunotherapy to prevent post-HCT relapse of AML. GDT cell expansion was successful in all 12 treated patients,… pic.twitter.com/YBEp4ylFe9
— AML Hub (@AML_Hub) February 13, 2025
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 14, 2025
Uday Popat, @MDAndersonNews, presents results from a phase II trial evaluating myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa and venetoclax (Cladillac) conditioning regimen for allo-HSCT in 49 patients with very… pic.twitter.com/DCU5X6oeT3
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Robert Zeiser, @UniFreiburg, discusses strategies for preventing AML relapse after transplant, such as targeting MDM2 to increase MHC-II expression and using anti-TIM-3 antibodies to enhance GVL effects.
Follow our live feed for more updates:… pic.twitter.com/LciOn4K2xC
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Venessa Kennedy, @Stanford, shares insights on next generation allogeneic transplant strategies for AML. They highlight potential approaches, including CD117 targeting with briquilimab + NMA conditioning in high-risk AML/MDS; cellular… pic.twitter.com/PEZCOzuBbY
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Yi-Bin Chen, @harvardmed, provides insights into the role of MRD testing in post-HCT maintenance for AML. He discusses various maintenance treatment options, including FLT3 inhibitors, HMAs, IDH1/2 inhibitors, and menin inhibitors, and their… pic.twitter.com/e1JqEJOIPt
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 15, 2025
Danielle Kirkey, @fredhutch, discusses a novel immunotherapeutic target —CLEC2A—which is highly enriched in high-risk KMT2Ar and monosomy 7 AML. Preclinical studies showed that CLEC2A CAR T cells exhibited target-restricted AML killing and… pic.twitter.com/tvTSrNpcvC
CONGRESS | #Tandem25 | PRESENTATION@DrMonzrAlMalki, @cityofhope, presents preliminary results from the phase I ALLOHA trial (NCT05473910) evaluating TSC-100 and TSC-101 TCR-T cells as maintenance treatment post-HCT to prevent relapse in patients with AML, ALL, or MDS undergoing… pic.twitter.com/YiN8CJOPrx
— AML Hub (@AML_Hub) February 16, 2025
CONGRESS | #Tandem25 | PRESENTATION
— AML Hub (@AML_Hub) February 16, 2025
John F. DiPersio @DiPersioLab, @WashUOncology, presents preliminary results from the phase I/II VBP101 trial (NCT04849910) of trem-cel, a CD33-deleted allograft, followed by GO maintenance in patients with CD33+ AML or MDS with high-risk of… pic.twitter.com/BotOezTnHV
Your opinion matters
2 votes - 23 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox